Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CytoNext
- Development stage
- Unknown
- Lead developer
- Cytonex
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
CytoNext is a biological therapeutic developed by Cytonex, consisting of stem cell conditioned media (SCCM) derived from mesenchymal stem cells. Administered via an inhaler, it is designed to treat respiratory conditions including chronic obstructive pulmonary disease (COPD), lung fibrosis, asthma, and COVID-19, including post-recovery. The product's mechanism of action centers on its secretome, which includes the antiviral effector protein IFITM3 (Interferon-induced transmembrane protein 3). IFITM3 works by inhibiting the fusion of viral and host cell membranes, thereby preventing viral entry into host cells. Additionally, the conditioned media contains a variety of growth factors and anti-inflammatory cytokines that facilitate tissue repair and modulate the immune response in the pulmonary environment.
- Brand names
- CytoNext
- Other names
- Stem Cell Conditioned MediaSCCMCytonex Stem Cell Conditioned Media
Beyond the preview
Go deeper on CytoNext.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytoNext.